Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants.
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D016667:Bacterial Capsules; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005312:Fetal Blood; D006192:Haemophilus Infections / Q000276:immunology* / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D019741:Haemophilus influenzae type b / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D022242:Pneumococcal Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D011135:Polysaccharides, Bacterial / Q000009:adverse effects / Q000627:therapeutic use*; D016742:Preconception Care; D011247:Pregnancy; D016896:Treatment Outcome; D018074:Vaccines, Conjugate / Q000627:therapeutic use